Former Pfizer Exec Named President Bayer Consumer
Bayer HealthCare LLC announces the appointment of Erica L. Mann as the new President of its Consumer Care Division, a global business, with operations in more than 140 countries and 2009 net sales of EUR 3,080 million. Mann also becomes a member of the Bayer HealthCare Executive Committee. She will join the company effective March 14, 2011.
Mann most recently served as President and General Manager of Pfizer Nutritional Health, a global business unit with operations in more than 80 countries, and was a member of the Pfizer Senior Management Team.
Mann joined Pfizer upon its acquisition of Wyeth, where as Senior Vice President, Nutrition, she helped establish the shape and strategic direction of the new nutrition business unit, and, as Managing Director, Wyeth Australia & New Zealand, introduced a range of significant medicines and nutritionals. Mann also led Wyeth's Pharmaceutical business in South Africa for over a decade as Managing Director and Chief Executive Officer, and holds the distinction of being the first female CEO of a pharmaceutical company in that country.
In addition, she has held executive positions in several industry organizations, including the South African Pharmaceutical Manufacturers' Association and Medicines Australia, as well as the International Association of Infant Food Manufacturers. Earlier in her career, she held positions of increasing responsibility at Lederle Laboratories, Johnson & Johnson and Eli Lilly & Company.
In addition, she has held executive positions in several industry organizations, including the South African Pharmaceutical Manufacturers' Association and Medicines Australia, as well as the International Association of Infant Food Manufacturers. Earlier in her career, she held positions of increasing responsibility at Lederle Laboratories, Johnson & Johnson and Eli Lilly & Company.
The Consumer Care Division of Bayer was formed in 1995 and has become the No. 2 OTC company in the world, and the division has also seen significant growth and development of its Intendis prescription dermatology business.